Theravance Biopharma (NASDAQ:TBPH) received a $55.00 price objective from stock analysts at Cantor Fitzgerald in a report released on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 157.97% from the company’s previous close.

TBPH has been the subject of several other reports. Piper Jaffray Companies set a $55.00 target price on Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, July 31st. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $44.25.

Shares of TBPH stock traded up $0.06 during trading on Friday, reaching $21.32. 14,256 shares of the company’s stock were exchanged, compared to its average volume of 310,674. The stock has a market capitalization of $1.21 billion, a PE ratio of -5.34 and a beta of 1.75. Theravance Biopharma has a twelve month low of $15.18 and a twelve month high of $35.48. The firm’s fifty day moving average price is $18.68 and its 200-day moving average price is $21.23.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.50. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. The firm had revenue of $26.15 million for the quarter, compared to analyst estimates of $13.92 million. Sell-side analysts anticipate that Theravance Biopharma will post -4.28 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Norges Bank bought a new position in shares of Theravance Biopharma during the fourth quarter valued at $22,422,000. Nuveen Asset Management LLC bought a new position in shares of Theravance Biopharma during the second quarter valued at $3,610,000. Nomura Holdings Inc. lifted its holdings in shares of Theravance Biopharma by 250.0% during the second quarter. Nomura Holdings Inc. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $3,562,000 after acquiring an additional 150,000 shares during the period. BlackRock Inc. lifted its holdings in shares of Theravance Biopharma by 3.1% during the second quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock valued at $62,587,000 after acquiring an additional 116,009 shares during the period. Finally, Fosun International Ltd bought a new position in shares of Theravance Biopharma in the first quarter valued at about $2,386,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Further Reading: Why do analysts give a neutral rating?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.